JP2020519659A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519659A5
JP2020519659A5 JP2019563101A JP2019563101A JP2020519659A5 JP 2020519659 A5 JP2020519659 A5 JP 2020519659A5 JP 2019563101 A JP2019563101 A JP 2019563101A JP 2019563101 A JP2019563101 A JP 2019563101A JP 2020519659 A5 JP2020519659 A5 JP 2020519659A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
group
pharmaceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019563101A
Other languages
English (en)
Japanese (ja)
Other versions
JP7218306B2 (ja
JP2020519659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032726 external-priority patent/WO2018213281A1/en
Publication of JP2020519659A publication Critical patent/JP2020519659A/ja
Publication of JP2020519659A5 publication Critical patent/JP2020519659A5/ja
Application granted granted Critical
Publication of JP7218306B2 publication Critical patent/JP7218306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019563101A 2017-05-15 2018-05-15 神経変性疾患を治療するための組成物 Active JP7218306B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506226P 2017-05-15 2017-05-15
US62/506,226 2017-05-15
PCT/US2018/032726 WO2018213281A1 (en) 2017-05-15 2018-05-15 Compositions for treating neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2020519659A JP2020519659A (ja) 2020-07-02
JP2020519659A5 true JP2020519659A5 (enExample) 2021-07-26
JP7218306B2 JP7218306B2 (ja) 2023-02-06

Family

ID=64274594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563101A Active JP7218306B2 (ja) 2017-05-15 2018-05-15 神経変性疾患を治療するための組成物

Country Status (13)

Country Link
US (3) US11214540B2 (enExample)
EP (1) EP3634394B1 (enExample)
JP (1) JP7218306B2 (enExample)
KR (1) KR102614814B1 (enExample)
CN (1) CN110869011B (enExample)
AU (1) AU2018269964B2 (enExample)
BR (1) BR112019023851A2 (enExample)
DK (1) DK3634394T3 (enExample)
ES (1) ES3063712T3 (enExample)
IL (1) IL270251B2 (enExample)
MX (1) MX388366B (enExample)
WO (1) WO2018213281A1 (enExample)
ZA (1) ZA201907238B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
CN116867488A (zh) * 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性(amd)的组合物
CA3212092A1 (en) * 2021-03-19 2022-09-22 Cognition Therapeutics, Inc. Compositions and methods for treating neurologic diseases
CN121652104B (zh) * 2026-02-04 2026-05-05 成都施贝康生物医药科技有限公司 一种哌啶衍生物、药物组合物、及其用途和制备方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
DE2753278A1 (de) 1977-11-30 1979-05-31 Basf Ag Aralkylpiperidinone
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
DE3222152A1 (de) 1982-06-12 1983-12-15 Bayer Ag, 5090 Leverkusen Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
FI81713C (fi) 1983-01-31 1990-12-10 Lilly Co Eli Foerfarande och djurfoderpremix foer befraemjande av tillvaexten, foerbaettring av utnyttjandegraden av foder eller minskning av fetthalten i koett hos ett husdjur.
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
JPH01305085A (ja) * 1988-05-31 1989-12-08 Yamanouchi Pharmaceut Co Ltd ピリジルチアゾリジンカルボン酸アミド誘導体
JPH02215789A (ja) * 1989-02-15 1990-08-28 Yamanouchi Pharmaceut Co Ltd チアゾロ[3,4―a]ピラジン誘導体
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 4―(4―アルコキシフェニル)―2―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU702629B2 (en) 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
JPH06321781A (ja) 1993-05-13 1994-11-22 Yamanouchi Pharmaceut Co Ltd 血小板活性化因子拮抗剤
JPH0714147A (ja) 1993-06-25 1995-01-17 Dainippon Printing Co Ltd 磁気記録媒体および磁気記録媒体の記録方法
JPH07145147A (ja) * 1993-11-26 1995-06-06 Yamanouchi Pharmaceut Co Ltd 安息香酸誘導体又はその塩
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
DE19529411A1 (de) * 1995-08-10 1997-02-13 Bayer Ag Substituierte Tetrahydro-5-nitro-pyrimidine
JP3522930B2 (ja) 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6235731B1 (en) 1996-04-24 2001-05-22 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
JP4329290B2 (ja) 2000-10-06 2009-09-09 田辺三菱製薬株式会社 脂肪族含窒素五員環化合物
WO2002070647A2 (en) 2001-03-05 2002-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
WO2003016274A2 (en) 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
UA82057C2 (en) 2001-12-14 2008-03-11 Каунсил Оф Сайентифик Энд Индастриал Рисёрч COMPOSITION basED on AR-D-turmeron and α- anD β-turmeron FOR TREATING NEUROCEREBROVASCULAR DISORDERS
JP4329381B2 (ja) 2002-04-04 2009-09-09 田辺三菱製薬株式会社 医薬組成物
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
EP1635805A4 (en) 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US7829562B2 (en) 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
BRPI0413709A (pt) 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
SK50802006A3 (sk) 2004-03-12 2007-03-01 Egis Gy�gyszergy�r Nyrt. Kombinovaná farmaceutická kompozícia na inhibíciupoklesu kognitívnych funkcií
AU2005247251A1 (en) 2004-05-31 2005-12-08 Kaneka Corporation Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 a-베타 올리고머의 정제 방법,당해 비확산성 a-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
EP1896005A4 (en) 2005-06-15 2009-11-11 Darrick S H L Kim SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
CA2644093A1 (en) 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. Extracts and methods comprising curcuma species
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2007126473A2 (en) 2006-04-10 2007-11-08 Oligomerix, Inc. Oligomerization of amyloid proteins
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
EP2066692B1 (en) 2006-09-08 2012-01-11 VIB, vzw Means and methods for the production of amyloid oligomers
US7723377B2 (en) 2006-09-29 2010-05-25 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20080131233A1 (en) 2006-10-17 2008-06-05 Yao Chun I Plate-shaped fastener device
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS
US7968524B2 (en) 2007-05-15 2011-06-28 Helicon Therapeutics, Inc. Methods of enhancing long term memory formation by inhibition of Gpr12
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
WO2009048631A1 (en) 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
EP2303920A4 (en) 2008-07-25 2011-11-09 Abbott Lab SS-AMYLOID PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PREPARATION METHODS AND COMPOSITIONS COMPRISING THE SAME OR OLIGOMERIC ANALOGUES, AND USES THEREOF
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
AU2010213794A1 (en) 2009-02-10 2011-09-01 Abbott Laboratories Agonists and antagonists of the S1P5 receptor, and methods of uses thereof
JP5730280B2 (ja) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド 非カノニカル生物学的活性を有するヒスチジル−tRNAシンテターゼスプライスバリアントを含む組成物および方法
WO2010118055A1 (en) 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20150160228A1 (en) 2010-02-05 2015-06-11 Susan Catalano Compositions and method for determining the efficacy of amyloidosis treatments
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2012027548A1 (en) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
US20140378460A1 (en) 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US20200338045A1 (en) 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN110283082A (zh) 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法
CN116867488A (zh) 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性(amd)的组合物

Similar Documents

Publication Publication Date Title
JP2020023528A5 (enExample)
JP2019521988A5 (enExample)
RU2004131641A (ru) Новые соединения
JP2023524821A5 (enExample)
JP2018070614A5 (enExample)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
RU2006101452A (ru) Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора
JP2020503341A5 (enExample)
JP2020529994A5 (enExample)
JP2017524733A5 (enExample)
JP2005511699A5 (enExample)
RU2015143610A (ru) Лечение катаплексии
JP2009536620A5 (enExample)
JP2016516074A5 (enExample)
JP2015531764A5 (enExample)
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2017511377A5 (enExample)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
RU2009137779A (ru) Композиции, содержащие (s)-2-амино-1-(4-хлорфенил)-1-[4-(1н-пиразол-4-ил)фенил]этанол, в качестве модуляторов протеинкиназ
JP2018522861A5 (enExample)
JP2017510595A5 (enExample)
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
JP2019535723A5 (enExample)